| Name | Title | Contact Details |
|---|
Alberta Conservation Association is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx`s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx`s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, expected to enter the clinic in the second half of 2022.
Vaxin is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Vaxin is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products. Our mission at Vaxin is to protect and preserve public health by providing effective and safe vaccines that prevent disease outbreak.
Turner Biosystems is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Klox Technologies is a Canadian specialty pharmaceutical company focusing on the development and commercialization of its proprietary BioPhotonic technology platform. This non-invasive, pathology-specific topical treatment platform harnesses the power of light and photo activated oxygen-rich gel formulations to target various skin and soft tissue disorders. With franchises in dermatology, wound care, and oral health, Klox Technologies is well positioned to capitalize on significant market opportunities. We believe that our dedication to providing healthcare professionals with novel and effective treatment solutions will allow patients to experience positive results without some of the side effects associated with existing treatments. Klox Technologies’ senior management team has over 80 years of combined experience in the biotechnology, pharmaceutical, and medical devices industries. We continue to research, develop, and commercialize solutions based on our BioPhotonic technology platform for a growing and aging population that is seeking more effective and less invasive treatment options to improve their health and quality of life.